You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

CLINICAL TRIALS PROFILE FOR HUMAN RABIES VIRUS IMMUNE GLOBULIN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for human rabies virus immune globulin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02040090 ↗ Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects Completed Kamada, Ltd. Phase 2/Phase 3 2013-04-01 The purpose of this study is to: 1. Evaluate the safety and tolerability of KamRAB in comparison with Human rabies immune globulin (HRIG) comparator product. 2. To assess whether KamRAB interferes with the development of self active antibodies when given simultaneously with active rabies vaccine, as compared to the HRIG comparator product, also given in conjunction with the active rabies vaccine.
NCT02564471 ↗ Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis. Completed Kansas State University Phase 4 2016-11-11 This is an exploratory trial to evaluate the effect of antimalarial drugs on the immune response generated by rabies vaccine when administered for post-exposure prophylaxis. This study will use the FDA approved post-exposure prophylaxis vaccine regimen (without rabies immune globulin) in the presence or absence of an FDA-approved malaria chemoprophylaxis regimen.
NCT02564471 ↗ Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis. Completed Walter Reed Army Institute of Research (WRAIR) Phase 4 2016-11-11 This is an exploratory trial to evaluate the effect of antimalarial drugs on the immune response generated by rabies vaccine when administered for post-exposure prophylaxis. This study will use the FDA approved post-exposure prophylaxis vaccine regimen (without rabies immune globulin) in the presence or absence of an FDA-approved malaria chemoprophylaxis regimen.
NCT02564471 ↗ Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis. Completed State University of New York - Upstate Medical University Phase 4 2016-11-11 This is an exploratory trial to evaluate the effect of antimalarial drugs on the immune response generated by rabies vaccine when administered for post-exposure prophylaxis. This study will use the FDA approved post-exposure prophylaxis vaccine regimen (without rabies immune globulin) in the presence or absence of an FDA-approved malaria chemoprophylaxis regimen.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for human rabies virus immune globulin

Condition Name

Condition Name for human rabies virus immune globulin
Intervention Trials
Rabies 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for human rabies virus immune globulin
Intervention Trials
Rabies 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for human rabies virus immune globulin

Trials by Country

Trials by Country for human rabies virus immune globulin
Location Trials
United States 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for human rabies virus immune globulin
Location Trials
New York 1
Minnesota 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for human rabies virus immune globulin

Clinical Trial Phase

Clinical Trial Phase for human rabies virus immune globulin
Clinical Trial Phase Trials
Phase 4 1
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for human rabies virus immune globulin
Clinical Trial Phase Trials
Completed 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for human rabies virus immune globulin

Sponsor Name

Sponsor Name for human rabies virus immune globulin
Sponsor Trials
Kamada, Ltd. 1
Kansas State University 1
Walter Reed Army Institute of Research (WRAIR) 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for human rabies virus immune globulin
Sponsor Trials
Other 2
Industry 1
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.